Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus

News Item Dermatology

CD19 CAR T cell therapy effective for systemic lupus erythematosus

J. Gelfand

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Rheumatology

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Edward M. Vital et al.

Summary: This study characterizes the efficacy and safety of anifrolumab in patients with moderate-to-severe SLE. It shows that anifrolumab has consistent efficacy and safety across different subgroups of patients. However, the limited sample size in some subgroups limits the conclusions about treatment benefit with anifrolumab.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

Andreas Mackensen et al.

Summary: A study of five patients with refractory systemic lupus erythematosus treated with anti-CD19 CAR T cell therapy showed remission of SLE disease in all patients after 3 months, and long-term drug-free remission was maintained during follow-up.

NATURE MEDICINE (2022)

Add to Collection

Article Cell Biology

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Monique G. P. van der Wijst et al.

Summary: Autoantibodies against type I interferons have been identified in some patients with critical COVID-19, with higher prevalence in severe cases. The longitudinal dynamics and functional effects of these antibodies on circulating leukocytes remain unclear.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences